ClinicalTrials.gg
Status unknownNCT05615519Updated Dec 5, 2022

Validation of a Smartphone-based Intelligent Diagnosis and Measurement for Strabismus

An observational study in Strabismus, Exotropia and Esotropia, sponsored by Sun Yat-sen University. Status unknown at 1 site in China. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by Sun Yat-sen University · Observational

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
3 Years and older
Sex
All
01

Study summary

The current measurement methods of strabismus include the corneal light reflection method, prism alternate covering, etc., which especially rely on the subjective experience of doctors, and there is a large error between different measurers, leading to serious underestimation of strabismus prevalence and insufficient care for strabismus patients. Here, the investigators established and validated an artificial intelligence system to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests. Three-dimensional reconstruction methods are used to digitize the parameters of head and eye positions. This system has been integrated into a smartphone platform to be further validated through hospital-based and population-based clinical trials.

02

Conditions studied

  • Strabismus
  • Exotropia
  • Esotropia
  • Vertical Strabismus

Keywords

  • Mobile health
  • Artificaial intelligence medicine
  • Pediatric ophthalmology
03

In context

Strabismus

142 studies on the registry are indexed under Strabismus; 31 are open to participants now.

This study's planned enrollment of 300 is above the median of 96 across 54 observational studies indexed under Strabismus.

Browse Strabismus studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Outpatients from strabismus \& optometry departments or participants from the internet.

Eligibility criteria

Inclusion Criteria:

The quality of facial videos should be clinically acceptable.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Eligible participants for smartphone-based strabismus measurement and diagnosis

    Facial videos dataset Facial videos were collected using smartphone and following the programmatic cover tests.

    Diagnostic Test: A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.

Interventions

  • Diagnostic testA new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.

    Digital ruler of strabismus

06

What researchers measure

Primary outcomes

  1. The effectiveness of smartphone-based diagnosis

    The accurate and the area under curve of the smartphone-based diagnosis.

    Time frame: Baseline

  2. The consistency between manual and smartphone measurement

    Agreement between the manual and automated tests was represented in Bland-Altman plots and concordance correlation coefficients.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Haotian Lin, Ph.D · Contactgddlht@aliyun.com · +86-020-87330274
    • Haotian Lin, Ph.D · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Mar 2023, 2 months later.

Of 26 observational studies under Strabismus, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 50. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 14, 2022
StartEst.
Dec 2, 2022
Primary completionEst.
Mar 1, 2023
CompletionEst.
Apr 1, 2023
Last update
Dec 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05615519
Responsible party
Haotian Lin (Clinical Professor, Sun Yat-sen University) — Principal investigator
First posted
Nov 14, 2022
Start date
Dec 2, 2022 (estimated)
Primary completion
Mar 1, 2023 (estimated)
Completion
Apr 1, 2023 (estimated)
Last update
Dec 5, 2022

Study contacts

Haotian Lin, M.D., Ph.D
Contact
haot.lin@hotmail.com
8613802793086
Ruixin Wang, M.D., Ph.D
Contact
ruiruiw413@aliyun.com
8615360458084

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion